FDA panel to weigh revoking key use of Abbott drug - BusinessWeek

[INCIID News Feed]

USA Today
<img alt="" height="1" width="1" />
FDA panel to weigh revoking key use of Abbott drug
BusinessWeek
A panel of advisers to the Food and Drug Administration will consider this week whether to revoke a key indication from Abbott&#39;s blockbuster cholesterol drug Trilipix. Trilipix is a fibrate, a drug that lowers blood fats called ...
Drug Study a Setback for AbbottNew York Times
Abbott Drug Faces US Scrutiny Over Lack of Heart BenefitsBloomberg
FDA weighs revoking approval of Abbott&#39;s TrilipixChicago Tribune
Medical News Today -NASDAQ
all 160 news articles &raquo;


More...